Salort-Llorca C,
Mínguez-Serra MP, Silvestre-Donat FJ. Maxillary osteonecrosis associated to antiangiogenic
drugs. Med Oral Patol Oral Cir Bucal. 2011 Mar 1;16 (2):e137-8.
doi:10.4317/medoral.16.e137
1. Bagan J, Scully C, Sabater V,
Jimenez Y. Osteonecrosis of the jaws in patients
treated with intravenous bisphosphonates (BRONJ): A
concise update. Oral Oncol.
2009;45:551-4.
doi:10.1016/j.oraloncology.2009.01.002
PMid:19251474
2. Allen MR, Burr DB. The pathogenesis of bisphosphonate-related
osteonecrosis of the jaw: so many hypotheses, so few
data. J Oral Maxillofac Surg. 2009;67:61-70.
doi:10.1016/j.joms.2009.01.007
PMid:19371816
3. Aragon-Ching JB, Dahut WL. Osteonecrosis of
the jaw and the use of antiangiogenic agents: just an
association? Oncologist. 2008;13:1314.
doi:10.1634/theoncologist.2008-0206
PMid:19088325
4. Aragon-Ching JB, Ning
YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, et
al. Higher incidence of Osteonecrosis of the Jaw
(ONJ) in patients with metastatic castration resistant prostate cancer treated
with anti-angiogenic agents. Cancer Invest. 2009;27:221-6.
doi:10.1080/07357900802208608
PMid:19235596 PMCid:2648132
5. Christodoulou C, Pervena A, Klouvas
G, Galani E, Falagas ME, Tsakalos G, et al. Combination of bisphosphonates
and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology.
2009;76:209-11.
doi:10.1159/000201931
PMid:19212145
6. Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G
3rd, Huryn JM. Osteonecrosis
of the jaw related to bevacizumab. J
Clin Oncol. 2008;26:4037-8.
doi:10.1200/JCO.2007.15.5424
PMid:18711196
7. Greuter S, Schmid F, Ruhstaller T, Thuerlimann B. Bevacizumab-associated osteonecrosis
of the jaw. Ann Oncol. 2008;19:2091-2.
doi:10.1093/annonc/mdn653
PMid:18977851 PMCid:2733125
8. Ayllon J, Launay-Vacher
V, Medioni J, Cros C, Spano JP, Oudard S. Osteonecrosis of the jaw under bisphosphonate
and antiangiogenic therapies: cumulative toxicity
profile? Ann Oncol. 2009;20:600-1.
doi:10.1093/annonc/mdn788
PMid:19188135
9. Brunello A, Saia G, Bedogni
A, Scaglione D, Basso U. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell
carcinoma. Bone.
2009;44:173-5.
10. Bagán J, Blade J, Cozar JM, Constela M, García Sanz R, Gómez Veiga F, et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated
with bisphosphonates. Med
Oral Patol Oral Cir Bucal. 2007;12:E336-40.
PMid:18849018